6566 POSTER Updated Safety and Efficacy Results From RADIANT-2 – a Randomized, Double-blind, Multicenter, Phase III Trial of Everolimus + Octreotide LAR Vs Placebo + Octreotide LAR in Pts With Advanced Neuroendocrine Tumours (NET)

✍ Scribed by Ricci, S.; Ruszniewski, P.; Tomasetti, P.; Jehl, V.; Saletan, S.; Yao, J.C.; Pavel, M.

• Book ID: 122915323
• Publisher: Elsevier Science
• Year: 2011
• Tongue: English
• Weight: 41 KB
• Volume: 47
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/S0959-8049(11)71877-9